Ⓐ
PeptiBrief
Evidence Library
comparative_clinical_study · 2008

Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia

Zozulia AA|et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
lowPMID · 18454096Verified
View source
Plain-English summary

The study reported similar anxiolytic effects, with additional anti-asthenic findings for Selank.

Population
Patients with generalized anxiety disorder or neurasthenia
Sample size
62
Intervention
Selank compared with medazepam
Outcomes measured
Psychometric anxiety and global clinical measures
Key findings
Promising but low-certainty comparative evidence.
Limitations
Small study|Comparator rather than placebo|Regional publication|Limited blinding information
Risk of bias
High.
Citation
Zozulia AA|et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova
Linked peptides in the PeptiBrief database
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.